Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients

被引:24
作者
Luo, Liu-Ying
Soosaipillai, Antoninus
Grass, Linda
Diamandis, Eleftherios P.
机构
[1] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
关键词
human kallikrein 6; human kallikrein 10; ovarian cancer biomarkers; ascites fluid; tissue kallikreins;
D O I
10.1159/000094693
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Human kallikreins 6 (hK6) and 10 (hK10) are secreted serine proteases. We previously found that hK6 and hK10 are highly overexpressed in epithelial ovarian tumors and demonstrated that serum levels of hK6 and hK10 are valuable biomarkers for ovarian cancer diagnosis and prognosis. Our aim is to purify and characterize these two kallikreins from ascites fluid of ovarian cancer patients. Methods: Protein concentrations of hK6 and hK10 in ovarian cancer ascites fluids were measured with ELISA-type immunoassays. hK6 and hK10 were purified from the ascites fluids with immunoaffinity columns, followed by reverse-phase high performance liquid chromatography. Purified hK6 and hK10 were then subjected to N-terminal sequencing. Enzymatic analyses were performed with synthetic fluorogenic peptides. Results: hK6 and hK10 were present in ovarian cancer ascites fluid at concentrations ranging from 0.2-571 and 0.7-220 mu g/l, respectively. The majority of hK6 and hK10 in the ascites fluids were present in the free (uncomplexed) form. Both hK6 and hK10 purified from the ascites fluid were zymogens with a molecular mass of 30 kDa. Purified hK6 exhibited trypsin-like enzymatic activity, whereas no enzymatic activity was observed for purified hK10. The enzymatic activity of hK6 could be suppressed by a neutralizing monoclonal antibody. Conclusions: The majority of hK6 secreted by the ovarian tumor cells into the ascites fluid are present in the uncomplexed, zymogen form, possessing weak trypsin-like enzymatic activity. All hK10 present in ovarian cancer ascites fluids are in the uncomplexed, zymogen form and have no detectable enzymatic activity. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:227 / 234
页数:8
相关论文
共 44 条
[1]   A novel protease homolog differentially expressed in breast and ovarian cancer [J].
Anisowicz, A ;
Sotiropoulou, G ;
Stenman, G ;
Mok, SC ;
Sager, R .
MOLECULAR MEDICINE, 1996, 2 (05) :624-636
[2]   Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation [J].
Bayés, A ;
Tsetsenis, T ;
Ventura, S ;
Vendrell, J ;
Aviles, FX ;
Sotiropoulou, G .
BIOLOGICAL CHEMISTRY, 2004, 385 (06) :517-524
[3]   Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system [J].
Bernett, MJ ;
Blaber, SI ;
Scarisbrick, IA ;
Dhanarajana, P ;
Thomspon, SM ;
Blaber, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :24562-24570
[4]   Targeting kallikrein 6-proteolysis attenuates CNS inflammatory disease [J].
Blaber, SI ;
Ciric, B ;
Christophi, GP ;
Bernett, MJ ;
Blaber, M ;
Rodriguez, M ;
Scarisbrick, IA .
FASEB JOURNAL, 2004, 18 (03) :920-+
[5]  
Borgoño CA, 2004, MOL CANCER RES, V2, P257
[6]  
Borgoño CA, 2003, CANCER RES, V63, P9032
[7]   Favorable prognostic value of tissue human kallikrein 11 (hk11) in patients with ovarian carcinoma [J].
Borgoño, CA ;
Fracchioli, S ;
Yousef, GM ;
de la Longrais, IAR ;
Luo, LY ;
Soosaipillai, A ;
Puopolo, M ;
Grass, L ;
Scorilas, A ;
Diamandis, EP ;
Katsaros, D .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (04) :605-610
[8]  
Dhar S, 2001, CLIN CANCER RES, V7, P3393
[9]   Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications [J].
Diamandis, EP ;
Yousef, GM ;
Soosaipillai, AR ;
Grass, L ;
Porter, A ;
Little, S ;
Sotiropoulou, G .
CLINICAL BIOCHEMISTRY, 2000, 33 (05) :369-375
[10]   Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis [J].
Diamandis, EP ;
Borgoño, CA ;
Scorilas, A ;
Yousef, GM ;
Harbeck, N ;
Dorn, J ;
Schmalfeldt, B ;
Schmitt, M .
TUMOR BIOLOGY, 2003, 24 (06) :299-309